Mixlab’s Post

Healing Paws and Claws: Animal Wound Care Essentials The Global Animal Wound Care market was valued at USD 1.04 billion in 2022 and is projected to reach USD 1.83 billion by 2030, registering a CAGR of 7.3% for the forecast period 2023- 2030 Read the Full Report: https://lnkd.in/dJnQiCcz Key Players of the Animal Wound Care Market :  3M, BKK B. Braun Melsungen AG , Neogen Corporation., Indian Immunologicals Limited., Johnson & Johnson ., Bayer Consumer Care AG, Virbac, Medtronic, Sonoma Pharmaceuticals , Advancis Veterinary , KRUUSE, Robinson Healthcare Ltd, Dechra Pharmaceuticals PLC, JORGENSEN LABS LLC., Silverglide, Sentrx Animal Care, Inc. , Innovacyn. (US), KCI Licensing Inc., Huvepharma nv #CompetitiveInsights #Research #MarketingConsultants #MarketReports #DataAnalytics #BusinessConsultant #ConsultingServices #MarketInsights #BusinessIntelligence #MarketTrends #AnimalWoundCare #AnimalWoundCareMarket

Get a Free Sample Report, Visit - https://bit.ly/3tbbXu4 The #global #veterinary #therapeutics market was valued at USD 42128.39 million in 2022 and is expected to reach USD 72379.12 million in 2030, with a #CAGR of 7.20% during the #forecast period 2023-2030. => The introduction and development of a new drug are considered major driving factors for the veterinary therapeutics market globally. => The increasing research and development activities in the field of veterinary therapeutics for effective drug development is providing a lucrative opportunity for the growth of the market. => North America is expected to hold a maximum share of the veterinary therapeutics market. #Market #Players Boehringer Ingelheim Bayer Dechra Pharmaceuticals PLC Ceva Santé Animale Elanco Merck Animal Health Virbac Merial Zoetis Vetoquinol Global Norbrook Laboratories ltd Heska IDEXX Aratana Therapeutics Inc. Biogénesis Bagó Phibro Animal Health Abaxis, Inc. Neogen Corporation HIPRA Nexvet Biopharma, now part of Zoetis scil animal care company GmbH More Insights on this Report, Speak to our Analyst @ https://bit.ly/48sIyf1   #marketanalytics #consulting #marketsize #investments #opportunities #growth #innovation

🔬 Accelerate Animal Health Drug Development with AcademicLabs! 🚀 Unlike those in the pharmaceutical industry, the absence of specialized pipeline databases makes it difficult for animal health companies to analyze competitor activities and identify potential licensing or collaboration opportunities. AcademicLabs can be your game-changer, by providing you with easy access to targeted information! 🌐💡 At AcademicLabs, we offer a treasure trove of information, including details about experts, companies, patents, publications, research groups, funded projects, and clinical trials of human drugs that can have potential implications for the animal health sector. With our help, you make data-driven decisions that help you easily Discover, Develop, and Register. Discover the power of AcademicLabs at https://lnkd.in/graF8zH and accelerate your animal health drug development journey! 🚀🐶🐱 #AnimalHealth #DrugDevelopment #Innovation #AcademicLabs

🔬 Accelerate Animal Health Drug Development with AcademicLabs! 🚀 The absence of specialized pipeline databases, akin to those in the pharmaceutical industry, makes it difficult for animal health companies to analyze competitor activities and identify potential licensing or collaboration opportunities. AcademicLabs can be your game-changer, by providing you with easy access to targeted information! 🌐💡 At AcademicLabs, we offer a treasure trove of information, including details about experts, companies, patents, publications, research groups, funded projects, and clinical trials of human drugs that can have potential implications for the animal health sector. With our help, you make data-driven decisions that help you Discover, Develop and Register with ease. Discover the power of AcademicLabs at https://lnkd.in/graF8zH and accelerate your animal health drug development journey! 🚀🐶🐱 #AnimalHealth #DrugDevelopment #Innovation #AcademicLabs

READ: New CVM Draft Guidance for Industry #285 – Changes Are A-Coming https://lnkd.in/ekqmSTZy "Since the retirement of CVM Guidance for Industry (GFI) #42 “Animal Drug Manufacturing Guidelines – Series of Four Guidelines,” which was withdrawn in October 2019, the animal health industry has been anticipating guidance from the CVM on these topics." Click to Read More! Author: Becky Welton #AnimalDrugs #FDA #RegulatoryAffairs

FDA JUST RELEASED: Special Considerations, Incentives, and Programs to Support the Approval of New Animal Drugs for Minor Uses and for Minor Species Guidance for Industry This version of the guidance replaces the version made available May 2008. This guidance is intended to assist those interested in pursuing #FDAapproval of #newanimaldrugs intended for minor uses in major species (minor use) or for use in #minorspecies. It outlines the basic requirements and special considerations for these approvals and describes the incentives available to encourage the development of new animal drugs for minor uses and minor species (#MUMSdrugs). Many of those seeking approval for MUMS drugs are new to the new animal drug approval process. To better assist those who may be unfamiliar with the approval process, topics are presented in the order in which they commonly arise in the development of a MUMS drug. Although #FDA intends for this guidance to be generally useful for all parties that may pursue approval of a MUMS drug, some portions of this document contain information that applies specifically to applications for approval of MUMS drugs intended for use in #aquaticspecies. This document includes citations to the applicable sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or to the implementing regulations in Title 21 of the Code of Federal Regulations (21 CFR), and references to related guidance documents. Appendix 1 – Additional Resources lists all Guidance for Industry (#GFI) documents referred to in this guidance and provides hyperlinks to these GFIs and other sources of information relevant to the topics included in this document. Appendix 2 – Acronyms & Definitions provides a glossary of many terms and acronyms used in this document. These are included to provide a quick reference and may repeat some terms defined in the body of the document. #animalhealth #veterinary If you like this post follow me on LinkedIn

**PRESS RELEASE** Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has reached an agreement in principle for the sale of its entire interest (the “Interest”) in STEM Animal Health Inc. (“STEM”) to a third party multi-national pharmaceutical company (the “Purchaser”) on a cash-free debt-free basis for US $8,000,000 (the “Transaction”), subject to adjustments in accordance with the terms of the agreement in principle, as well as other consideration including the net cash held in STEM (estimated at CND $600,000) and a working capital adjustment (estimated at CND $350,000). Overall, it is anticipated that the sale of STEM Animal Health will net Kane Biotech in excess of CND $11,500,000 (including the cash deposits already received, as noted below). The Purchaser is not a Non-Arm’s Length Party (as that term is defined by the TSX Venture Exchange) of the Company. In connection with the Transaction, but not included in the net amount of the sale, the Company will be eligible for a US $750,000 sales-based milestone payment and will also be entering into product development and transitional manufacturing agreements with STEM. The Company anticipates using the net proceeds from the Transaction to repay its outstanding loan to Pivot Financial I Limited Partnership in the amount of approximately CND $6,700,000, and for general working capital purposes. Prior to the completion of the Transaction, as previously announced, the Company received an aggregate of US $1,525,000 from the Purchaser in cash deposits that it applied towards the sale price for the Interest. Accordingly, the Company is expected to receive US $6,475,000 upon the completion of the Transaction. “We are pleased with the outcome of this transaction,” said Marc Edwards, President & CEO of Kane Biotech. “Kane Biotech will be receiving full value for the successful animal health business that it created allowing the Company to significantly strengthen its balance sheet and narrow its focus on human health biofilm solutions”. Prior to the completion of the Transaction, the Company owned a 2/3 interest in STEM. The remaining 1/3 interest was owned by an arm’s length third party. In accordance with the policies of the TSX Venture Exchange, the Transaction must be consented to by shareholders of the Company holding over 50% of the common shares of the Companydue to the fact that the Transaction constitutes a sale of more than 50% of the Company’sassets, business or undertaking. The Company anticipates that it will be able to satisfy this requirement through the written consent of shareholders of the Company holding more than 50% of the common shares of the Company.            The closing of the Transaction is subject to the approval of the TSX Venture Exchange. Read the full press article: https://lnkd.in/d9yAFgrU #KaneBio #PetCare #PressRelease 

𝐀𝐧𝐢𝐦𝐚𝐥 𝐖𝐨𝐮𝐧𝐝 𝐂𝐚𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭𝐞𝐝 𝐭𝐨 𝐑𝐞𝐚𝐜𝐡 $𝟐.𝟎 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟐𝟗 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐚𝐭 https://lnkd.in/drUD5cWP The global animal wound care market in terms of revenue was estimated to be worth $1.3 Billion in 2023 and is poised to reach $2.0 Billion by 2029, growing at a CAGR of 7.4% from 2023 to 2029. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Elanco (Shanghai) Animal Health Co Ltd 3M Medtronic BKK B. Braun Melsungen AG Virbac Neogen Corporation Jørgen KRUUSE A/S Sonoma Pharmaceuticals Ethicon, Inc. Dechra Pharmaceuticals Manufacturing Jazz Medical Smith+Nephew KeriCure Medical Advancis Veterinary CareTech LABORATORIES Robinson Healthcare Ltd MILA International, Inc. Sentrx Animal Care, Inc. Mccord Research Llc PrimaVet Inc. Innovacyn Indian Immunologicals Limited Silverglide Surgical Technologies Vernacare Vetoquinol India Animal Health Pvt Ltd #animalwoundcare #animalwoundcaremarket

Global Animal Drug Compounding Market The Global Animal Drug Compounding Market Size is valued at 2.07 billion in 2022 and is predicted to reach 4.12 billion by the year 2031 at an 8.17% CAGR during the forecast period for 2023-2031. Read Press Release:https://lnkd.in/dgux5FSQ #animal #drug #compounding #marketresearch #marketresearchreport

According to a new market research report published by Global Market Estimates, the global veterinary biomarkers market is projected to grow at a CAGR of 12.7% from 2023 to 2028. The Factors driving the growth of this market includes, rising prevalence of animal diseases, advancement in biotechnology and molecular diagnostics, increasing investment in research and development, collaboration and partnership, personalized medicine in veterinary practice and regulatory support. Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and in-depth TOC on “Global Veterinary Biomarkers Market - Forecast to 2028’’https://lnkd.in/dEzGKwmr #GlobalVeterinaryBiomarkersMarket #GlobalMarketEstimates #GME